Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial evaluating venetoclax in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma is curren…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL [Phase 1]
Phase 1 trial evaluating acalabrutinib with anti-CD20 therapy and venetoclax in relapsed/refractory or untreated chronic lymphocytic leukemi…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial evaluating acalabrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL [Phase 2]
An update on a Phase II trial evaluating MOR00208 in combination with lenalidomide for relapsed/refractory or untreated older patients with …
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax [Phase 1, Phase 2]
A Phase 1/2 trial evaluating pirtobrutinib (LOXO-305) as consolidation to eradicate minimal residual disease in chronic lymphocytic leukemia…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Mosunetuzumab for CLL MRD Clearance [Phase 1, Phase 2]
Clinical trial update for mosunetuzumab in chronic lymphocytic leukemia focusing on measurable residual disease clearance in Phase 1/2 studi…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma [Phase 1]
An ongoing Phase 1 clinical trial update for AS-1763 in adults with previously treated B-cell malignancies, including chronic lymphocytic le…
-
CLINICAL_TRIALS other · 2025-12-08Clinical Trial Update: Registry of the German CLL Study Group
Ongoing registry study by the German CLL Study Group recruiting participants for trials involving chronic lymphocytic leukemia, small lympho…
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas [Phase 1]
Phase 1 clinical trial update for ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select …
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Zanubrutinib and Venetoclax in CLL (ZANU-VEN) [Phase 2]
A Phase 2 clinical trial (ZANU-VEN) evaluating the combination of zanubrutinib and venetoclax for chronic lymphocytic leukemia and small lym…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study
A single-center cohort study is assessing biomarkers of cardiovascular complications in patients treated with second-generation BTK inhibito…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings
A French observational study of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in real-world settings is ongoing b…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) [Phase 2]
A Phase 2 clinical trial evaluating DZD8586 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma …
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial examined lenalidomide combined with blinatumomab for relapsed non-Hodgkin lymphoma across multiple subtypes and has compl…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy [Phase 2]
A Phase 2 trial is evaluating venetoclax as consolidation therapy in chronic lymphocytic leukemia or small lymphocytic lymphoma patients on …
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Watch and Wait or Worry and Wait in Indolent Lymphoma
An ongoing clinical trial at Seoul National University Hospital is evaluating watchful waiting versus proactive worry-and-wait strategies in…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) [Phase 2, Phase 3]
APEX-03 is a Phase 2/3 clinical trial evaluating ICP-248 in combination with orelabrutinib for treatment-naïve chronic lymphocytic leukemia …
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial [Phase 2]
The AVENUE-2 Phase 2 trial investigates acalabrutinib in combination with venetoclax for patients with refractory or recurrent chronic lymph…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating CTX112 in relapsed or refractory B-cell malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Long-term Follow-up Study of Patients Receiving CAR-T Cells
This clinical trial update outlines a long-term follow-up study of patients who received CAR-T cell therapy. Sponsored by the Medical Colleg…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma [Phase 1]
Phase 1 study of BAFF CAR-T cells (LMY-920) for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma is curren…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). [Phase 2]
Phase II clinical trial update for a time-limited combination therapy (pirtobrutinib, venetoclax, obinutuzumab) in recurrent Chronic Lymphoc…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial is evaluating ibrutinib with or without rituximab in patients with relapsed chronic lymphocytic leukemia and related lymphop…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [Phase 1]
Phase 1 clinical trial evaluating a triplet regimen of tafasitamab, acalabrutinib, and obinutuzumab for previously untreated chronic lymphoc…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study [Phase 2]
Phase 2 TaZA CLL study evaluating the combination of tafasitamab and zanubrutinib for newly diagnosed chronic lymphocytic leukemia or small …